A citation-based method for searching scientific literature

Leora Horn, Jeffrey R Infante, Karen L Reckamp, George R Blumenschein, Ticiana A Leal, Saiama N Waqar, Barbara J Gitlitz, Rachel E Sanborn, Jennifer G Whisenant, Liping Du, Joel W Neal, Jon P Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J Gibbons, Allison Holzhausen, Christine M Lovly, Heather A Wakelee. Clin Cancer Res 2018
Times Cited: 93



Luc Friboulet, Nanxin Li, Ryohei Katayama, Christian C Lee, Justin F Gainor, Adam S Crystal, Pierre-Yves Michellys, Mark M Awad, Noriko Yanagitani, Sungjoon Kim, AnneMarie C Pferdekamper, Jie Li, Shailaja Kasibhatla, Frank Sun, Xiuying Sun, Su Hua, Peter McNamara, Sidra Mahmood, Elizabeth L Lockerman, Naoya Fujita, Makoto Nishio, Jennifer L Harris, Alice T Shaw, Jeffrey A Engelman. Cancer Discov 2014
Times Cited: 585




List of shared articles



Times cited

An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.
Adela Patcas, Ana Florica Chis, Claudia Florentina Militaru, Ioana Roxana Bordea, Ruxandra Rajnoveanu, Ovidiu Florin Coza, Reem Hanna, Tamas Tiberiu, Doina Adina Todea. Bosn J Basic Med Sci 2022
1

Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Alice Indini, Erika Rijavec, Michele Ghidini, Claudia Bareggi, Donatella Gambini, Barbara Galassi, Paola Antonelli, Giulia Bettio, Clarissa Di Nubila, Francesco Grossi. Expert Opin Pharmacother 2020
6

New generation anaplastic lymphoma kinase inhibitors.
Angelo Delmonte, Marco Angelo Burgio, Alberto Verlicchi, Giuseppe Bronte, Paola Cravero, Paola Ulivi, Giovanni Martinelli, Lucio Crinò. Transl Lung Cancer Res 2019
12


Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer.
Hui Yu, Si Sun, Xingjiang Hu, Jinjing Xia, Jialei Wang, Haiquan Chen. Onco Targets Ther 2019
3

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease.
Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain J Gelibter. Drugs Context 2022
0

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.
Elisabeth Smolle, Valentin Taucher, Joerg Lindenmann, Philipp J Jost, Martin Pichler. Cancers (Basel) 2021
7

[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].
Peng Song, Li Zhang, Congcong Shang. Zhongguo Fei Ai Za Zhi 2018
3

Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.
Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo, Yingliang Wu. RSC Adv 2019
0

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
Anthony V Serritella, Christine M Bestvina. Thorac Surg Clin 2020
6

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.
Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao, Fang Wu. Front Oncol 2021
12

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan. Pharmaceuticals (Basel) 2020
29

Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018).
Yi-Min Liu, Chun-Nan Kuo, Jing-Ping Liou. Expert Opin Ther Pat 2020
4

[Pharmacology and Clinical Evaluation of Ensartinib Hydrochloride Capsule].
Yang Wang, Xiaobin Yuan, Jiayan Xiong, Zhidong Hao, Xingzhe Peng, Wanlin Chen, Lingling Cui, Hua Li, Xiulan Wang, Xiangbo He,[...]. Zhongguo Fei Ai Za Zhi 2020
2

Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong. J Hematol Oncol 2019
69

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance.
Zachary Schrank, Gagan Chhabra, Leo Lin, Tsatsral Iderzorig, Chike Osude, Nabiha Khan, Adijan Kuckovic, Sanjana Singh, Rachel J Miller, Neelu Puri. Cancers (Basel) 2018
72


Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors.
Yunju Nam, Dongkeun Hwang, Namdoo Kim, Hong-Seog Seo, Khalid B Selim, Taebo Sim. J Enzyme Inhib Med Chem 2019
8

Challenges and Opportunities in Cancer Drug Resistance.
Richard A Ward, Stephen Fawell, Nicolas Floc'h, Vikki Flemington, Darren McKerrecher, Paul D Smith. Chem Rev 2021
82

Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura. Curr Cancer Drug Targets 2019
29

Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, Tingjun Hou. J Med Chem 2019
49

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.
Joseph A Pinto, Luis E Raez, Gelenis Domingo. Expert Rev Respir Med 2020
4